In:
Current Topics in Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 21, No. 16 ( 2021-06), p. 1471-1487
Kurzfassung:
The role of the Galectin-3 (Gal-3) has already been explored in various somatic diseases,
considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegeneration,
so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a “second hit” later in life, and as a part of a unique systemic somatic
dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms
presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia.
Materialart:
Online-Ressource
ISSN:
1568-0266
DOI:
10.2174/1568026621666210611162420
Sprache:
Englisch
Verlag:
Bentham Science Publishers Ltd.
Publikationsdatum:
2021
SSG:
15,3